Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Accumulated Expenses (2020 - 2025)

Historic Accumulated Expenses for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Q3 2025 value amounting to $93.0 million.

  • Arcutis Biotherapeutics' Accumulated Expenses rose 7612.24% to $93.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.0 million, marking a year-over-year increase of 7612.24%. This contributed to the annual value of $66.8 million for FY2024, which is 9679.15% up from last year.
  • Per Arcutis Biotherapeutics' latest filing, its Accumulated Expenses stood at $93.0 million for Q3 2025, which was up 7612.24% from $87.9 million recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Accumulated Expenses registered a high of $93.0 million during Q3 2025, and its lowest value of $10.6 million during Q2 2021.
  • Moreover, its 5-year median value for Accumulated Expenses was $28.0 million (2023), whereas its average is $37.0 million.
  • Per our database at Business Quant, Arcutis Biotherapeutics' Accumulated Expenses plummeted by 1369.15% in 2021 and then skyrocketed by 12666.95% in 2024.
  • Arcutis Biotherapeutics' Accumulated Expenses (Quarter) stood at $25.5 million in 2021, then grew by 10.9% to $28.3 million in 2022, then increased by 19.84% to $33.9 million in 2023, then skyrocketed by 96.79% to $66.8 million in 2024, then skyrocketed by 39.2% to $93.0 million in 2025.
  • Its Accumulated Expenses stands at $93.0 million for Q3 2025, versus $87.9 million for Q2 2025 and $65.8 million for Q1 2025.